Spectacular #RAKNYE 2022 Fireworks Show Sets Two GUINNESS WORLD RECORDS™ Titles, Mesmerising Thousands of Visitors
1.1.2022 14:06:00 EET | Business Wire | Press release
Welcoming hundreds of thousands of spectators from around the world, the Ras Al Khaimah New Year’s Eve Celebrations (#RAKNYE 2022) dazzled all with a never-before-seen fireworks display that smashed two GUINNESS WORLD RECORDS™ titles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211231005082/en/
#RAKNYE 2022 Two GUINNESS WORLD RECORDS™ titles (Photo: AETOSWire)
Rising majestically from the Arabian Gulf, the fireworks display featured innovative pyrotechnic performances spanning an area of over 4.7 kilometres. The 12-minute spectacle was specially choreographed to reflect the joy of reunion with six themes set to epic orchestral music.
A spokesperson of the organising committee said: “#RAKNYE2022 is our tribute to the leadership and people of Ras Al Khaimah and the UAE not only as we celebrate the 50th Anniversary of our nation but also in preparation for the Next 50 Years. With this event, we once again underlined the reputation of Ras Al Khaimah as the leading tourism destination welcoming visitors from across the world.”
#RAKNYE 2020 fireworks display was conducted in a six-act sequence starting with the countdown just before midnight. Ushering in the New Year with a spectacular tower of lights, 1,055.8 metres high, the next act was a ‘Happy New Year’ message written in the sky with firework drones. This was followed by a tribute to the UAE backed by orchestral music, celebrating the achievements of the nation and its people. It segued to the next act when hundreds of drones displayed the UAE’s 50th Anniversary logo. The finale was in two parts – a multi-colour display of lights and a super-massive expanse of white that illuminated the skyline.
Setting the first GUINNESS WORLD RECORDS™ title for the ‘Highest Altitude Multirotor/Drone Fireworks Display’ was the tower of fireworks 1,055.8 metres high, taller than any skyscraper in the world. The second GUINNESS WORLD RECORDS™ title was for the ‘Most Remote Operated Multirotors/Drones Launching Fireworks Simultaneously’, when 452 drones launched fireworks simultaneously to create the ‘Happy New Year’ visual in the sky.
The celebration was organised by following all social distancing protocols and other safety guidelines with the support of the National Authority for Emergency, Crisis & Disaster Management and the Ministry of Health & Prevention. Visitors watched the festivities from special Viewing Decks along Al Marjan Island and Al Hamra Village. Video link here
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211231005082/en/
Contact information
Nivine William
ASDA’A BCW | +97144507600
nivine.william@bcw-global.com
www.asdaa-bcw.com | www.arabyouthsurvey.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom